QualityDipStocks / Health Care · Pharmaceuticals
United Therapeutics UTHR
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen, trading below our fair value estimate, 13% over its Market Value.
- Fair value est.
- $736.26+23%
- Market Value
- $531.92price +13%
- Off 52-wk high
- at the high
- Risk vs market
- Lowbeta 0.21
5 bullish · 4 bearish See why
Key levels
Every level vs today’s $598.72
- 52-wk lowlowest close, 1 year$437.33−27.0%
- Market Valueavg paid since Sep 8$531.92−11.2%
- 52-wk highhighest close, 1 year$598.72at the price
- PriceFri Oct 30 close$598.72you are here
- Fair value est.base case$736.26+23.0%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, UTHR’s free cash flow would need to grow about 11% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much UTHR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.7× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.21
- Volatility
- 34% vs 13% SPY
- Correlation SPY
- 0.08
- Correlation QQQ
- 0.04
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $736.26, 23% above the price.
ProfitabilityOperating margin of 44% over the last 12 months.
Cash returnsShare count down 5.2% in a year: $2.5B of buybacks over 12 months.
ValuationP/E of 20.9× vs a 29.2× median for the 86 Health Care companies we cover.
GrowthSales compounded 18% a year from FY2022 to FY2025.
Top bearish points 4 of 5
GrowthSales growth slowed to 2% over the last 12 months, from 18% a year over the prior three fiscal years.
ProfitabilityOperating margin narrowed to 46.9% in FY2025 from 50.9% in FY2023 (SEC filings).
QualityDoesn’t pass our quality screen: sales down vs the year-ago quarter.
ValuationTrades 12.6% above its Market Value of $531.92, the average price paid since the Sep 8 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on United Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
P/E 20.9 · FCF yield 4.0% · ROE 19%
Valuation
- P/E
- 20.9×Health Care median 29.2×
- Price / FCF
- 25.1×
- FCF yield
- 4.0%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 8.69×
- Price / book
- 4.28×
- Market cap
- $27.4Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $3.2B
- Sales growth, 12 months
- +2.5%vs the 12 months before
- Sales growth, 3 yrs
- +18.0%/yrfrom FY2022
- Diluted EPS, 12 months
- $27.91
- EPS growth, last FY
- +13.1%
- Net income, 12 months
- $1.3B
- Net income growth
- +6%12 months vs before
Profitability
- Gross margin
- 86.1%
- Operating margin
- 44.4%
- Net margin
- 41.6%
- FCF margin
- 34.6%
- Return on equity
- 19%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $2.7B
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 116.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $1.1B
- FCF growth, 12 months
- +2%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $2.5B9.1% of market cap
- Share count, 1 year
- −5.2%diluted shares vs a year ago
- Stock-based comp
- $155M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From United Therapeutics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $736.26 · MV $531.92 · FCF value $639.81
Assumes 15.0% growth for 5 years (revenue grew 18.0% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $23.86 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 5, 2026.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 70 · 5 days +1.9%
The business
FCF $1.1B · Sales −2%
- Free cash flow, 12 months$1.1B
- Free-cash-flow yield4.3%
- Free-cash-flow margin34%
- Gross margin86%
- Operating margin44%
- Return on invested capital17%
- Return on equity20%
- Sales growth (latest quarter vs year-ago quarter)−2%
- Net debt / EBITDA−1.0×
Next report
Nov 4
- DateWed Nov 4, before the open
- Consensus EPS$5.85
- Year-ago EPS$7.16
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
UTHR is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.